OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SPRO
Spero Therapeutics, Inc.
There isn't enough reported data to score SPRO yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SPRO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Weak | |
| Strong |
SPRO's balance sheet is currently strong, and its profitability is stable, but its revenue and cash flow are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SPRO PE Valuation
SPRO has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SPRO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect SPRO's losses to shrink, with revenue holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SPRO on earnings quality, reporting a profit while its opponent remains loss making.
SPRO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.49 | +$0.30 |
| Q2 2026 | $0.14 | +$1.12 |
| Q1 2026 | $0.27 | +$1.55 |
| Q4 2025 | $0.15 | +$1.42 |
| Q3 2025 | -$0.79 | -1088% |
| Q2 2025 | -$0.98 | -388% |
| Q1 2025 | -$1.28 | -391% |
| Q4 2024 | -$1.27 | -395% |
SPRO is still losing money, but far less than before: $0.49 per share over the past year, against $4.33 at its worst in mid-2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SPRO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
SPRO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $258K | -96% |
| Q4 2025 | $41.3M | +175% |
| Q3 2025 | $5.4M | -60% |
| Q2 2025 | $14.2M | +39% |
| Q1 2025 | $5.9M | -37% |
| Q4 2024 | $15M | -80% |
| Q3 2024 | $13.5M | -47% |
| Q2 2024 | $10.2M | +275% |
SPRO's revenue fell from its 2023 peak and has held roughly level since: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -2922% | -2671 points |
| Q4 2025 | 76% | +221 points |
| Q3 2025 | -145% | -7.4 points |
| Q2 2025 | -17% | +170 points |
| Q1 2025 | -251% | -100 points |
| Q4 2024 | -144% | -213 points |
| Q3 2024 | -138% | -130 points |
| Q2 2024 | -187% | +288 points |
SPRO's operating margin was −2922% last quarter, down 2671 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SPRO on cash generation, producing positive trailing cash flow while its opponent burns cash.
SPRO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$42.6M | -345% |
| Q2 2026 | -$5.4M | +$12.3M |
| Q1 2026 | $15.9M | +$19.9M |
| Q4 2025 | -$8.4M | +$15.1M |
| Q3 2025 | $17.4M | +37% |
| Q2 2025 | -$17.7M | +$1.1M |
| Q1 2025 | -$4M | -167% |
| Q4 2024 | -$23.4M | -$5.9M |
SPRO has burned cash in most quarters: −$40M over the past year, against −$28M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SPRO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +261K shares |
| 1 year | +3.5% | +1.9M shares |
| 3 years | +10% | +5.5M shares |
| 5 years | +96% | +28.6M shares |
| Available history | +206% | +39.2M shares |
SPRO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SPRO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2024 | -4.1x | Net Cash |
| Q1 2024 | -3.7x | Net Cash |
| Q4 2023 | -3.5x | Net Cash |
SPRO has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SPRO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.4 | Oversold |
| Stochastic | 9.2 | Oversold |
SPRO's weekly RSI is 26 (oversold) and its Stochastic is 9 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SPRO PE vs Healthcare Sector
| Metric | SPRO | Sector median | Relative |
|---|---|---|---|
| PE | 7.4x | 26x | 72% below |
| PE % | 55 | 29 | 26 pts above |
SPRO has the edge over OSCR on valuation relative to its sector.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SPRO on trend strength, trading above more of its moving averages.
SPRO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.11 | 9.9% below |
| 20 week MA | $1.28 | 22% below |
| 50 week MA | $2.00 | 50% below |
| 100 week MA | $1.81 | 45% below |
| 200 week MA | $1.63 | 39% below |
SPRO is in a downtrend: it's below all five of its weekly moving averages, and 39% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SPRO on returns for 2026, with the stronger performance.
SPRO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.4 | $22.0 | +111% |
| 2021 | $22.0 | $14.0 | -36% |
| 2022 | $14.0 | $1.59 | -89% |
| 2023 | $1.59 | $1.47 | -7.5% |
| 2024 | $1.47 | $1.03 | -30% |
| 2025 | $1.03 | $2.32 | +125% |
| 2026 YTD | $2.32 | $1.00 | -57% |
SPRO's yearly returns have swung widely, from +125% in 2025 to −89% in 2022. It's down 57% so far in 2026.